It was an absolute pleasure to speak with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around the initial safety and clinical responses of patients with juvenile-onset systemic sclerosis treated with CD34-selected peripheral blood ASCT (NCT03630211).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
Questions
- What have been the initial safety and clinical responses of patients undergoing this procedure? (0:19)
- Based on these findings, how should ASCT eligibility criteria be expanded? (3:43)
- What future studies are planned? (6:53)
Disclosures: Kathryn Torok has nothing to disclose in relation to this video.
Correspondence: Kathryn Torok, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh |UPMC Children’s Hospital of Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224, Tel: (412) 692-5081 | Fax: (412) 692-5054 | kathryn.torok@chp.edu
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
